Biotech Values

[DewDiligence]

AMGN, Daiichi Sankyo ink Japanese-commercialization deal for Humira/Avastin/Herceptin FoBs:

http://finance.yahoo.com/news/amgen-daiichi-sankyo-announce-agreement-010000498.html

Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan, while Amgen will have a limited right to co-promote the products.

…Specific financial terms of the agreement were not disclosed.

AMGN has a pre-existing worldwide (ex-Japan) partnership with AGN (formerly Watson) to develop FoBs for Avastin, Rituxan, Herceptin, and Erbitux (#msg-70097496), and AMGN is developing (ex-Japan) FoBs on its own for Humira (#msg-123830467) and Remicade.